Osteoporosis Diagnosis and Management

Introduction to Osteoporosis Diagnosis

Patients with frequent fractures, such as rib fractures, secondary to minimal trauma, should undergo dual-energy x-ray absorptiometry (DXA) of the spine and hip, along with vertebral fracture assessment (VFA) or spinal radiography to identify potential subclinical vertebral fractures, as recommended by the European Journal of Nuclear Medicine and Molecular Imaging and Arthritis and Rheumatology 1, 2
The gold standard for diagnosing osteoporosis is DXA scan of the lumbar spine and hip, according to the European Journal of Nuclear Medicine and Molecular Imaging and Arthritis and Rheumatology 1, 2

DXA scan of the lumbar spine and hip should be completed as soon as possible to diagnose osteoporosis, as recommended by the European Journal of Nuclear Medicine and Molecular Imaging and Arthritis and Rheumatology 1, 2
VFA or spinal radiography should be used to detect subclinical vertebral fractures, which significantly increases future fracture risk independent of BMD, according to the Annals of the Rheumatic Diseases and Arthritis and Rheumatology 1, 3

Chronic inhaled corticosteroid use increases fracture risk, particularly at the hip and spine, according to the Annals of the Rheumatic Diseases 3
Recurrent fractures from minimal trauma are diagnostic of osteoporosis regardless of BMD, as stated by the Annals of the Rheumatic Diseases 3
Age is an independent risk factor for osteoporosis, according to the Annals of Internal Medicine 4

The 10-year fracture risk should be calculated using the FRAX tool, as recommended by the European Journal of Nuclear Medicine and Molecular Imaging and Arthritis and Rheumatology 1, 2
For patients on corticosteroids, the FRAX calculation should be adjusted, according to Arthritis care & research 5
The following table summarizes the risk stratification categories:

Risk Category	Characteristics
Very High Risk	Prior osteoporotic fracture(s), BMD T-score ≤-3.5, high-dose glucocorticoids, 10-year major osteoporotic fracture risk ≥20%
High Risk	BMD T-score ≤-2.5, 10-year major osteoporotic fracture risk 10-19%, glucocorticoid use ≥7.5 mg/day for >3 months
Moderate Risk	Intermediate fracture risk by FRAX, Z-score <-3 at hip or spine, >10%/year loss of BMD at hip or spine
Low Risk	No significant risk factors, low FRAX score

Patients can be stratified into these four risk categories based on factors such as prior osteoporotic fractures, BMD T-score, glucocorticoid use, and 10-year major osteoporotic fracture risk, according to the American College of Rheumatology 2, 6, 5, 7, 8

Adequate calcium intake (1000-1200 mg daily) and vitamin D supplementation (600-800 IU daily) are recommended for all patients, as suggested by the American College of Rheumatology 2, 6, 5, 7, 8
Weight-bearing and muscle resistance exercises, balance exercises to prevent falls, smoking cessation, and limiting alcohol consumption are also recommended, according to the American College of Rheumatology 2, 6, 5, 7, 8
Anabolic agents (teriparatide, abaloparatide, romosozumab) are conditionally recommended for Very High Risk patients, while oral bisphosphonates are strongly recommended for High Risk patients, as recommended by the American College of Rheumatology 7
For Moderate Risk patients, oral or IV bisphosphonates, denosumab, or anabolic agents are conditionally recommended, according to the American College of Rheumatology 7

Clinical fracture risk reassessment is recommended every 12 months for patients continuing glucocorticoids, as suggested by the American College of Rheumatology 5
FRAX with BMD testing is recommended every 1-3 years for adults ≥40 years not on osteoporosis medication, and every 2-3 years for adults on osteoporosis medication, according to the American College of Rheumatology 5
More frequent monitoring (yearly BMD until stable) is recommended for Very High Risk patients, as suggested by the American College of Rheumatology 8

FRAX has limitations, including not being validated for adults <40 years, underestimating risk in patients on very high-dose glucocorticoids, and not adequately accounting for frailty, multiple fractures, or fall history, as noted by the American College of Rheumatology 7
Imminent fracture risk is highest in the 1-2 years following a major osteoporotic fracture, requiring prompt intervention, according to the American College of Rheumatology 6
Treatment gaps exist, with approximately 70% of high-risk patients not receiving appropriate assessment and treatment, highlighting the need for fracture liaison services, as recommended by the American College of Rheumatology 6
Special populations, such as patients with glucocorticoid-induced osteoporosis, require specific risk assessment and management approaches, according to the American College of Rheumatology 2, 5